Kenvue Cuts Annual Profit Forecast on Weakness in Cold, Flu Meds Demand

Reuters2023-10-26

Kenvue (KVUE.N) on Thursday cut its annual profit forecast, as it expects lower demand for its cough, cold and flu medicines and increased impact from a stronger dollar.

Kenvue shares slipped 2.43% after posting financial results.

Benadryl-maker Kenvue and peer Haleon, which makes Sensodyne toothpaste, have seen sustained demand for their consumer health products as people prioritize spending on essentials amid a cost-of-living crisis in some parts of the world.

Kenvue, the spun-off unit of Johnson & Johnson (JNJ.N), now expects full-year adjusted profit between $1.26 and $1.28 per share, compared with its previous forecast of $1.26 to $1.31 per share.

The consumer health company, however, reported higher revenue of $3.92 billion for the quarter ended Oct. 1, compared with $3.79 billion, a year earlier, aided by strong sales for its over-the-counter medicines in the quarter.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1178483780?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2023-10-26 18:46","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1178483780","market":"us","top_or_hot":-1,"title":"Kenvue Cuts Annual Profit Forecast on Weakness in Cold, Flu Meds Demand","media":"Reuters","content":"<html><head></head><body><p>Kenvue <u>(KVUE.N)</u> on Thursday cut its annual profit forecast, as it expects lower demand for its cough, cold and flu medicines and increased impact from a stronger dollar.</p><p>Kenvue shares slipped 2.43% after posting financial results.</p><p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/08f94cc1b2376d5e3c76c2bfd1142bdb\" tg-width=\"806\" tg-height=\"842\"/></p><p style=\"text-align: start;\">Benadryl-maker Kenvue and peer Haleon, which makes Sensodyne toothpaste, have seen sustained demand for their consumer health products as people prioritize spending on essentials amid a cost-of-living crisis in some parts of the world.</p><p>Kenvue, the spun-off unit of Johnson &amp; Johnson <u>(JNJ.N)</u>, now expects full-year adjusted profit between $1.26 and $1.28 per share, compared with its previous forecast of $1.26 to $1.31 per share.</p><p style=\"text-align: start;\">The consumer health company, however, reported higher revenue of $3.92 billion for the quarter ended Oct. 1, compared with $3.79 billion, a year earlier, aided by strong sales for its over-the-counter medicines in the quarter.</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Kenvue Cuts Annual Profit Forecast on Weakness in Cold, Flu Meds Demand</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nKenvue Cuts Annual Profit Forecast on Weakness in Cold, Flu Meds Demand\n</h2>\n\n<h4 class=\"meta\">\n\n2023-10-26 18:46 北京时间&nbsp;&nbsp;&nbsp;<strong>Reuters</strong>\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Kenvue (KVUE.N) on Thursday cut its annual profit forecast, as it expects lower demand for its cough, cold and flu medicines and increased impact from a stronger dollar.Kenvue shares slipped 2.43% ...</p>\n\n<a href=\"\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"JNJ","symbol_name":"强生","start_time":0,"source_url":"","article_id":"1178483780","we_media_id":"1036604489","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1178483780","pubTimestamp":1698317170,"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"summary":"Kenvue  on Thursday cut its annual profit forecast, as it expects lower demand for its cough, cold and flu medicines and increased impact from a stronger dollar.Kenvue shares slipped 2.43% after posting financial results.Benadryl-maker Kenvue and peer Haleon, which makes Sensodyne toothpaste, have seen sustained demand for their consumer health products as people prioritize spending on essentials amid a cost-of-living crisis in some parts of the world.Kenvue, the spun-off unit of Johnson & Johns","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"JNJ":"强生","KVUE":"Kenvue Inc"},"translate_title":"Kenvue因感冒、流感药物需求疲软下调年度利润预期","themeId":"c0d77e622a6742cf8335299f8317b4b4","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"JNJ":1.1,"KVUE":1.1},"content_text":"Kenvue (KVUE.N) on Thursday cut its annual profit forecast, as it expects lower demand for its cough, cold and flu medicines and increased impact from a stronger dollar.Kenvue shares slipped 2.43% after posting financial results.Benadryl-maker Kenvue and peer Haleon, which makes Sensodyne toothpaste, have seen sustained demand for their consumer health products as people prioritize spending on essentials amid a cost-of-living crisis in some parts of the world.Kenvue, the spun-off unit of Johnson & Johnson (JNJ.N), now expects full-year adjusted profit between $1.26 and $1.28 per share, compared with its previous forecast of $1.26 to $1.31 per share.The consumer health company, however, reported higher revenue of $3.92 billion for the quarter ended Oct. 1, compared with $3.79 billion, a year earlier, aided by strong sales for its over-the-counter medicines in the quarter.","kind":null,"is_publish_news":true,"is_publish_highlight":true,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":2,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.2","shortVersion":"4.29.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1178483780"}